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Summary 
Autoimmune diseases including connective tissue diseases and bullous diseases are 
life-threatening diseases. Recent clinical and experimental approaches have 
demonstrated that B cells play critical roles in autoimmune disease manifestation by 
well-established autoantibody-mediated mechanisms but also by a variety of other 
functions. These B cell functions are under regulation of B cell antigen receptor 
(BCR)-induced signals and by specialized cell surface coreceptors, or "response 
regulators," which inform B cells of their microenvironment. These response regulators 
include CD19 and CD22. CD19 and CD22 do not merely regulate BCR signals 
independently, but they have their own regulatory network. CD19 regulates CD22 
phoshorylation by augmenting Lyn kinase activity, while CD22 inhibits CD19 
phosphorylation via SHP-1. Importantly, these molecules consisting of this “CD19/CD22 
loop” are significantly related with autoimmune phenotype in mice. Thus, CD19/CD22 
loop may be a potential therapeutic target in autoimmune disease by modulating B cell 
signaling. 
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1. Introduction 
Recent studies have revealed that B lymphocytes have more diverse functions in the 
immune system than were appreciated (1). Disruption of these functions leads to 
autoimmunity, in which B cells do not merely serve as passive producers of 
autoantibodies but also play a pivotal role via nonconventional mechanisms, including 
antigen presentation, cytokine production, and modulation of other immune cells. These 
functions of B cells depend on the activity of intrinsic and B cell antigen receptor 
(BCR)-induced signals. BCR signals are amplified, perpetuated, or suppressed through 
the regulation by specialized cell surface coreceptors, or "response regulators," which 
inform B cells of their microenvironment (2, 3). These response regulators include CD19, 
CD22, CD72, and Fcγ receptor IIb (FcγRIIb), and can be categorized into positive 
regulators or negative regulators. CD19 acts as a positive response regulator by 
establishing a Src-family protein tyrosine kinase (PTK) activation amplification loop that 
regulates basal signaling thresholds and intensifies Src-family PTK activity following 
BCR ligation as well as maintaining phosphatidylinositol (PI) 3-kinase and Vav 
activation (4). By contrast, CD22, CD72, and FcγRIIb provide negative feedback 
pathways to downregulate BCR signaling through the recruitment of tyrosine 
phosphatases including SHP-1 and/or SHIP (5, 6). Altering expression/function of these 
signaling components in mice can lead to autoimmune phenotypes. For example, a 
deficiency of Lyn, a Src-family PTK, leads to a severe lupus-like autoimmunity. This is 
likely to result from a failure of inhibitory feedback loops in which Lyn phosphorylates 
CD22 and CD72, triggering recruitment of SHP-1 to the plasma membrane, which then 
dampens BCR and/or CD19 signaling (5). Lyn deficiency also compromises an inhibitory 
pathway involving FcγRIIb and SHIP. In human, genetic and/or functional abnormalities 
have been found in these B cell signaling molecules as well. Herein we will discuss our 
current understanding of the molecular mechanisms of how B cell signaling components, 
especially CD19 and CD22, govern the emergence and intensity of BCR-mediated 
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signals, and of how alterations in these tightly controlled regulatory activities contribute 
to autoimmunity in mice and humans. Precise understanding of these mechanisms will 
enable us to develop new therapeutic approaches of targeting specific components in B 
cell signaling pathways that govern the autoimmunity. This review focuses on recent 
advances in B cell signaling and autoimmune diseases, especially in terms with CD19 and 
CD22. 
 
2. Roles of B cells in autoimmune diseases 
It is widely accepted that antibodies (Abs) produced by autoreactive B cells can directly 
contribute to the pathogenesis in various autoimmune diseases. This is especially obvious 
in organ-specific autoimmune diseases such as pemphigus in dermatology field. For 
example, production of anti-desmoglein Ab in pemphigus directly causes interference of 
keratinocyte adhesion, resulting in blister formation. In systemic autoimmune diseases, 
autoantibodies can also play a pathogenic role (1). In systemic lupus erythematosus 
(SLE), immune complex deposition containing anti-double-stranded DNA Ab cause 
nephritis. In addition, anti-SS-A Ab is considered to play a pathogenic role in neonatal 
lupus. Animal models of systemic autoimmune diseases have also provided new insights 
into possible roles of autoantibodies. K/BxN mice, a spontaneous model of rheumatoid 
arthritis (RA), have hyperactive B cells that cause an increase in B cell numbers, 
hyper-γ-globulinemia, and autoantibody production (7). Injection of serum from sick 
K/BxN mice into healthy animals induces arthritis within days and the target of this 
arthritogenic Abs is shown to be glucose-6-phosphate isomerase, a ubiquitously 
expressed glycolytic enzyme (8). Furthermore, a potion of patients with RA, especially 
active patients, possess pathogenic autoantibodies reactive with glucose-6-phosphate 
isomerase that is expressed on the surface of the synovial lining as well as on the 
endothelial cells (9, 10). Thus, K/BxN mice model demonstrates that arthritis can be 
provoked by pathogenic autoantibodies.  
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Nonetheless, recent studies have clarified that B cells have more functions 
other than producing autoantibodies. Abnormalities of these B cell functions are likely to 
contribute to the induction or development of systemic autoimmune diseases. These 
functions include antigen-presentation, production of various cytokines, lymphoid 
organogenesis, differentiation of T effector cells, and influence of antigen-presenting 
dendritic cell function (11) (Fig. 1). For example, in lupus-prone MRL/lpr mice, 
elimination of B cells results in a complete abrogation of nephritis, vasculitis, and skin 
disease (12). Furthermore, MRL/lpr mice with B cells that cannot secrete Abs still 
develop nephritis and vasculitis (13). Therefore, these results suggest that, independent of 
autoantibodies, B cells are essential for disease expression by serving as 
antigen-presenting cells or by contributing to local inflammation through secreting 
cytokines (14). Thus, B cells play a critical role in systemic autoimmunity and 
manifestation of autoimmune diseases via a variety of functions.  
Recent clinical observations that B cell depletion is therapeutically beneficial 
in autoimmune disease patients have directly proved significant pathogenic roles for B 
cells in the initiation and progression of human autoimmune diseases. Treatment with 
monoclonal Ab against CD20, which is expressed by mature B cells, depletes B cells in 
vivo and ameliorates the manifestations of RA, SLE, idiopathic thrombocytopenic 
purpura and hemolytic anemia, as well as other immune-mediated diseases (15).  
 
3. B cell signaling and response regulators 
To facilitate protective immunity to pathogens while avoiding self-reactivity and 
autoimmunity, B cell responses to antigens are tightly regulated through intracellular 
signaling pathways. Importantly, this balanced regulation is achieved by signals 
generated through BCR and other cell-surface molecules that provide a context in the 
specific circumstances. Such response regulators can either positively or negatively 
regulate the context of BCR signaling, and thus establish signaling thresholds that control 
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the magnitude and duration of B cell activation. Positive response regulators that augment 
signals through BCR include CD19, while CD22, CD72, and FcγRIIb are among negative 
response regulators that dampen BCR signals (2, 16) (Fig. 2). 
 
4. CD19: a positive response regulator 
CD19 serves as a major positive response regulator in B cells. CD19 expression 
is restricted to the B cell lineage and follicular dendritic cells which function as 
antigen-presenting cells located in the murine spleen. CD19 is a 95-kDa immunoglobulin 
(Ig) superfamily member which has an extracellular region consisted of two C2-type 
Ig-like domains and a cytoplasmic region of ~240 amino acids including 9 conserved 
tyrosine residues. On B cell surface, CD19 forms a complex with CD21, CD81, and 
Leu-13 (CD225). CD21 is a receptor for complement C3 cleavage fragments and 
Epstain-Bar virus. Upon CD21 ligation, CD19 serves as a signal-transducing element of 
the complex. CD81 expression is critical for optimal CD19 expression and localization 
within lipid rafts (17). Accordingly, CD81-deificent mice exhibit a phenotype which 
resembles but is milder than that of CD19-deficient (CD19-/-) mice (18).  
The cytoplasmic region of CD19 contains 9 tyrosines, which are critical for 
CD19 function as a signaling molecule. While CD19 does not have enzymatic activity, 
CD19 acts as a cell-surface adapter protein that recruits signaling molecules through the 
interaction with phosphoryated tyrosines. CD19 tyrosines are phosphorylated by Lyn, a 
dominant Src-family PTK member in B cells (19, 20). CD19 regulates a variety of 
extracellular stimuli since CD19 is phosphorylated not only upon CD19/CD21 ligation 
but also BCR, CD38, CD40, or CD72 ligation as well as lipopolysaccharide stimulation 
(4, 21). Furthermore, simultaneous stimulation of CD19 with BCR, CD72, or CD40 
induces synergistic transmembrane signals. Tyrosine-phosphorylated CD19 provides 
SH2 recognition motifs that serve as docking sites for Src-family PTKs, Vav, and PI 
3-kinase (22). Furthermore, through the interaction with Src-family PTKs, CD19 
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upregulates and maintains Src-family PTK activity, and also facilitates and prolongs 
phosphorylation of other binding proteins, Vav and PI 3-kinase. Phosphorylated Vav can 
also recruit other SH2-domain-containing signaling molecules to this CD19 complex, 
which leads to downstream activation of mitogen-activated protein kinase family 
cascades. PI 3-kinase is another important effector molecule that interacts with CD19 
(23). PI 3-kinase is necessary for Bruton’s tyrosine kinase (Btk) activation. CD19 
deficiency results in decreased and transient Btk activation induced by BCR ligation, 
suggesting an important role of CD19 in maintaining activation of PI 3-kinase/Btk 
pathway (24, 25).  
CD19 expression is intrinsically and tightly regulated through B cell 
differentiation. CD19 is expressed by early pre-B cells from the time of Ig heavy chain 
rearrangement until plasma cell differentiation. CD19 expression gradually increase 
during the development, and B-1 cells express higher levels of CD19 than B-2 cells. By 
contrast, CD19 expression is not affected by B cell activation. Moreover, intrinsic CD19 
expression levels may determine a genetic predisposition to autoimmunity. CD19 
functions in vivo have been clarified using CD19-/- mice and CD19-transgenic 
(CD19-TG) mice that overexpress CD19 by ~3-fold (26-28). In general, CD19-/- mice are 
immunodeficient, while CD19-TG mice are autoimmune-prone (16). B cells from 
CD19-/- mice exhibit reduced proliferation to a variety of transmembrane signals, while B 
cells from CD19-TG mice show augmented proliferation to them. Serum Ig levels are 
decreased in CD19-/- mice and are increased in CD19-TG mice. CD19 expression on B 
cells also closely correlates with autoantibody production. Serum autoantibodies, such as 
anti-DNA Ab and rheumatoid factor, are decreased in CD19-/- mice, while they are 
increased in CD19-TG mice. Analysis using transgenic mouse model of autoreactive B 
cells and peripheral tolerance has revealed that CD19 overexpression disrupts peripheral 
tolerance in B cells and thereby induces autoantibody production (29).  
 
 - 7 - 
5. CD19/CD22 signaling loop 
CD22 is another B cell-specific transmembrane molecule critical for B cell survival and 
activation (30). CD22 is a 130-140-kDa protein that belong to “SIgLec” subclass of Ig 
superfamily. Extracellular domain of CD22 contain 5 (CD22α) or 7 (CD22β) Ig domains, 
while the cytoplasmic domain has 141 amino acids including 6 tyrosine residues, which 
are phosphorylated by Lyn (31). Amino acid sequences surrounding some of CD22 
tyrosines are considered as immunoreceptor tyrosine-based inhibitory motifs (ITIMs), 
which recruit potent tyrosine phosphatase SHP-1. CD22 phosphorylation also induces 
formation of a CD22/Shc/Grb-2 ternary complex (32). Therefore, CD22 plays an 
inhibitory role in cellular tyrosine and phospholipid phosphorylation via SHP-1 and SHIP 
activation. 
By contrast to the role of CD19 as a positive regulator, CD22 is generally 
categorized as a negative response regulator. Importantly, these two response regulators 
do not merely regulate BCR signals independently, but they have their own regulatory 
network (33) (Fig. 3). B cells from CD19-/- mice exhibit modest CD22 phosphorylation 
following BCR ligation, while CD19 tyrosine phosphorylation is increased in B cells 
from CD22-/- mice following BCR ligation (33). These evidences suggest that CD19 
expression facilitates CD22 phosphorylation and that CD22 expression inhibits CD19 
phosphorylation (4). CD19 positively regulates CD22 phsophorylation by augmenting 
Lyn kinase activity. Phosphorylated CD22 recruits SHP-1, which dephosphorylates 
CD19 in turn. Thus, CD19 and CD22 establish a loop that reciprocally regulates each 
other’s functions to modulate cellular tyrosine and phospholipid phosphorylation.  
Analysis of CD19/CD22 double-deficient (CD19-/-CD22-/-) mice has 
demonstrated that CD19 is upstream of CD22 function during B cell activation in most 
cases; CD22 deficiency does not influence the reduced serum Ig levels or the impaired Ab 
responses to T cell-dependent antigens that occurs in CD19-/- mice (33). Furthermore, 
numbers of splenic B cells and peritoneal B1 cells in CD19-/-CD22-/- mice are similarly 
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reduced as in CD19-/- mice (34, 35). Therefore, CD19 regulation on Src-family PTK 
activation is critical for the initiation of inhibitory regulation by CD22, and in turn CD19 
itself is a primary target of CD22/SHP-1. 
 
6. Switching off CD22 negative pathway by CD19 
While CD19 can function independent of the ligation of CD19 itself, co-engagement of 
CD19/CD21 complex with BCR results in synergistically enhanced signaling in response 
to complement-tagged antigens. Recent studies have shown that antigen binding leads to 
the translocation of BCR into plasma membrane lipid rafts that serve as platforms for 
efficient signal transduction. The binding of complement-tagged antigens stimulates the 
translocation of both the BCR and the CD19/CD21 complex into lipid rafts, resulting in 
prolonged residency in and signaling from the rafts, as compared to BCR cross-linking 
alone. When coligated to the BCR, the CD19/CD21 complex retards the internalization 
and degradation of the BCR (36).  
A mechanism for augmented signaling by simultaneous BCR and CD19 
ligation is explained by a finding that simultaneous BCR and CD19 ligation inhibits 
tyrosine phosphorylation of CD22, as well as SHP-1 recruitment to phosphorylated CD22 
(37, 38). Thus, activation occurs without engagement of CD22 inhibitory pathway. 
Simultaneous CD19 and BCR engagement may sequester the functionally available pool 
of Lyn away from CD22. Especially, the spatial relationship between the BCR, CD19 and 
CD22 is likely to be important to this process since CD22 locates outside of lipid rafts. 
Consistent with this, B cells from CD22-deficient and Lyn-deficient mice exhibit 
augmented BCR-induced [Ca2+]i responses, although simultaneous CD19 engagement 
does not further enhance the BCR-induced [Ca2+]i responses in Lyn- or CD22-deficient B 
cells (37). Thus, CD19 recruitment of Lyn and their preferential localization within 
detergent-insoluble lipid raft domains may preferentially activate selected signaling 
pathways regulated by the CD19/Lyn complex to the exclusion of other downstream 
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regulatory and effector pathways. 
 
7. CD19/CD22 autoimmune loop 
CD19/CD22 is not only important for normal B cell function, but increasing evidences 
have suggested that this unit serves as a critical signaling device to regulate the balance of 
autoimmunity in B cells. The components of the CD19/CD22 signaling loop, 
CD19/CD21, Lyn, CD22, and SHP-1, appear closely linked to autoimmune disorders (39, 
40) (Fig. 4). Altering their expression/function in mice leads to the manifestation of 
autoimmune phenotype. For example, Lyn-deficient mice and transgenic mice with 
hyperactivated form of Lyn both result in lupus-like disease (41). Transgenic mice that 
overexpress CD19 by ~3-fold lose tolerance and generate high titer of autoantibodies 
spontaneously including anti-double-stranded DNA Ab (40). Mice lacking CD22 have 
chronically activated B cells with various spontaneous autoantibody production including 
anti-cardiolipin Ab and anti-myeloperoxidase Ab (42). Motheaten viable (mev/mev) mice 
that have SHP-1 mutations produce elevated levels of spontaneous autoantibodies 
including anti-topoisomerase I (topo I) Ab, hyper-γ-globulinemia, and tissue deposition 
of immune complexes (43). Therefore, this “CD19/CD22 autoimmune loop” may be a 
potential therapeutic target in autoimmune disorders. 
 
8. Tight-skin mouse and CD19/CD22 autoimmune loop 
The Tight-skin (TSK) mouse, originally identified as a spontaneous mutation, is 
an animal model for human systemic sclerosis (SSc) (44). A tandem duplication within 
the fibrillin 1 gene is considered to responsible for the TSK phenotype (45). Fibrillin 1 is 
a major structural protein of a widely distributed class of connective tissue microfibrils. 
Homozygous mutation (TSK/TSK) results in embryo lethality, while heterozygous 
(TSK/+) mice survive, but develop cutaneous hyperplasia, pulmonary emphysema and 
cardiac hypertrophy.  
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The phenotype of TSK/+ mice appears regulated not only by fibrillin 1 mutation 
alone, since transgenic mice expressing a mutated fibrillin 1 gene develop subcutaneous 
hyperplasia, but not pulmonary emphysema and myocardial hypertrophy (46). Especially, 
an immunological component appears to influence the phenotype significantly. In 
addition to the fact that TSK/+ mice produce autoantibodies against SSc-specific target 
autoantigens including topo I, fibrillin 1, and RNA polymerase I, the lack of CD4 
expression in TSK/+ mice decreases subcutaneous hyperplasia but does not influence 
lung emphysema (47). Additionally, disruption of one or both IL-4 alleles allows survival 
of 29 and 47%, respectively, of homozygous TSK/TSK mice (48). These mice do not 
exhibit subcutaneous hyperplasia but develop pulmonary emphysema. Collectively, these 
suggest that abnormal immune functions contribute to the complex phenotype of TSK 
mice. Consistent with this, polymorphisms of the transforming growth factor-β1 
promoter in TSK mice have been also described (49). 
Analyses of B cells from TSK/+ mice have also demonstrated their skewed 
phenotype (50, 51). As in human SSc, TSK/+ B cells are persistently activated, 
characterized by reduced cell surface IgM level as well as upregulated MHC class II and 
CD23 density. B cells from human SSc patients show increased surface CD19 expression 
(52-54), while CD19 expression is not altered in B cells from TSK/+ mice. Nonetheless, 
remarkably, CD19 tyrosine phosphorylation is constitutively augmented (50), suggesting 
that the CD19 signaling pathway is intrinsically activated in TSK/+ B cells.  
Furthermore, TSK/+ B cells are hyperresponsive to BCR signaling. They exhibit 
exaggerated calcium responses and augmented activation of extracellular 
signal-regulated kinase (ERK) upon BCR crosslinking (51). BCR-induced CD19 
phosphorylation is also augmented compared with wild type B cells. Among many 
signaling molecules assessed, CD22 phosphorylation was specifically impaired in TSK/+ 
B cells. Decreased tyrosine phsphorylation of CD22 is consistent with CD19 
hyperphosphorylation in TSK/+ B cells, since CD19 is considered as a major target of 
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CD22 negative regulation via dephosphorylation by SHP-1 (33). Furthermore, 
CD22-deficient TSK/+ mice and CD22-deficient mice without TSK mutation showed 
identical [Ca2+]i response and ERK activation (51), suggesting that disruption of 
inhibitory signal provided by CD22 is the dominant mechanism of hyperactivated TSK/+ 
B cells. 
 Remarkably, CD19 deficiency in TSK/+ mice results in ~40% reduction of 
subcutaneous fibrosis (50). Therefore, B cells contribute to skin fibrosis in TSK/+ mice 
through a CD19-dependent pathway. TSK/+ mice exhibit hyper-γ-globulinemia and 
elevated autoantibody levels including anti-topo I Ab, both of which are also eliminated 
by CD19 deficiency. Reciprocally, anti-topo I Ab levels are significantly augmented in 
TSK/+ mice carrying CD19 transgene (51). Nonetheless, subcutaneous fibrosis does not 
increase in TSK/+ mice overexpressing CD19 or TSK/+ mice with CD22 deficiency (51). 
Therefore, while silencing B cell hyperactivation can reduce skin fibrosis, exaggerating B 
cell hyperactivation does not lead to further fibrosis. While the precise mechanism of how 
silencing B cell hyperactivation by CD19 pathway can influence skin fibrosis is yet to be 
solved, CD19 loss inhibits IL-6 production by TSK/+ B cells, which produce higher 
amount of IL-6 compared with wild type B cells when stimulated with anti-IgM Ab plus 
anti-CD40 Ab (50). Since recent reports have suggested that CD19 is a key regulator of 
cytokine production from B cells (55), CD19 expression may influence fibrosing process 
by controlling cytokine production such as IL-6.  
 
9. Conclusion 
Therapy using anti-CD20 Ab in human autoimmune diseases have elucidated pathogenic 
roles of B cells in various aspects and have provided a new paradigm how to treat them. 
Future therapeutic directions include modifying B cell signaling functions such as 
CD19/CD22 loop.  
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Figure Legends 
 
Figure 1. B cell functions that may contribute to autoimmunity. 
 
Figure 2. Positive and negative “response regulators” of B cells. Positive regulators 
include CD19, while negative regulators includes CD22, Cd72, and FCγRIIb. Each 
mnolecule has tyrosine residues that recruit signaling molecules upon phosphorylation. 
Particularly, specific tyrosine sequences in negative regulators are designated as ITIMs, 
which recruit phosphatase such as SHP-1 and SHIP. 
 
Figure 3. Regulation of CD19 and CD22 on BCR signaling.  
BCR ligation induces initial activation of Lyn, which phosphorylates CD19. 
Phosphorylated CD19 enhances and maintains Lyn activation, resulting in CD22 
phosphorylation. Phosphorylated CD22 recruits SHP-1, which then dephosphorylates 
CD19. 
 
Figure 4. CD19/CD22 autoimmune loop. 
Mice and human abnormalities of each molecule that are related to autoimmunity are 
shown in the square.  
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